Abstract
Introduction
Invasive fungal infections are a major cause of morbidity and mortality in patients with hematological malignancies receiving myelotoxic chemotherapy. The antifungal agent itraconazole has a broad spectrum of activity, which includes activity against Candida and Aspergillus, and is therefore an attractive antifungal prophylaxis for patients undergoing induction treatment for hematological malignancies. Despite the limited data on the efficacy of itraconazolebased systemic antifungal prophylaxis, it has been suggested that oral azole agents (e.g., fluconazole and itraconazole) are effective when treating patients with lymphoid malignancies and those who have undergone stem-cell transplantation (1, 2) . Recently, an oral solution of itraconazole with improved absorption and bioavailability has been developed which produces more consistent plasma concentrations than the conventional itraconazole capsules (3) . T a b l e 1 . S u mma r y o f Cl i n i c a l E v e n t s f o l l o wi n g CHOP a n d I t r a c o n a z o l e T r e a t me n t conazole solution.
Case Report
The seven ML patients in our study cohort (10) . One patient received oral itraconazole solution and the other received itraconazole injection; however, the doses of itraconazole were not reported in their study (10) (11, 12) . Another azole antifungal agent, fluconazole, also inhibits CYP3A-mediated metabolism of vincristine (13) . However, the degree of inhibition is much less than that of itraconazole (13) , consistent with the paucity of reports describing fluconazole-enhanced vincristine neurotoxicity.
Discussion

To our knowledge, this is the first report of oral itraconazole solution-enhanced vincristine neurotoxicity in Japanese adults with hematological malignancies. The adverse drug reactions that we report are similar to those occasionally observed with vincristine-based therapy. However, it is important to note that although our patients were undergoing vincristine treatment, the severe neurotoxicity observed in the majority of our ML cohort did not emerge until the initiation of oral itraconazole solution prophylaxis. Böhme et al first described enhanced vincristine neurotoxicity associated with itraconazole treatment in 1995 (4). In their report, severe neurotoxicity was observed in four out of 14 adult acute lymphocytic leukemia (ALL) patients who received induction chemotherapy (which included weekly vincristine injections) and antifungal prophylaxis with itraconazole capsules. It should be noted, however, that the capsule dose used in their report (400 mg/day) was twice the typical standard adult itraconazole dose (200 mg/day). Moreover, similar episodes of severe vincristine neurotoxicity have been reported in pediatric patients undergoing vincristine chemotherapy in combination with itraconazole prophylaxis (5-9). Recently, Chen et al reported itraconazoleenhanced vincristine neurotoxicity in two adult ALL patients
In addition, the human CYP3A4 and CYP3A5 genes are highly polymorphic (14) and it is possible that certain vari- 
